Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs

Simple item page
datacite.alternateIdentifier.citationXENOBIOTICA,Vol.50,1490-1493,2020
datacite.alternateIdentifier.doi10.1080/00498254.2020.1793031
datacite.creatorUrzua, Natalia
datacite.creatorMessina, Maria Jimena
datacite.creatorCaverzan, Matias
datacite.creatorPrieto, Guillermo
datacite.creatorLüders Post, Carlos
datacite.creatorErrecalde, Carlos
datacite.date2020
datacite.subject.englishLevofloxacin
datacite.subject.englishdogs
datacite.subject.englishpharmacokinetics
datacite.subject.englishsucralfate
datacite.titlePharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs
dc.date.accessioned2021-04-30T16:34:19Z
dc.date.available2021-04-30T16:34:19Z
dc.description.abstractThe study aims to establish the plasma pharmacokinetic parameters of levofloxacin in mixed-breed dogs, at a single dose of 5 mg/kg, intravenously, orally only and orally with sucralfate pre-treatment (1 g per animal), to evaluate its influence on antimicrobial absorption. Concentrations of levofloxacin in plasma were determined using high-performance liquid chromatography (HPLC) with fluorescence detection. After iv of levofloxacin, the mean (+/- SD) of AUC(0-24), Vz,t1/2 lambda z and MRT, was 19.05 +/- 6.4 mu g-h/ml, 2.43 +/- 0.5 L/kg, 7.93 +/- 1.41 hours and 8.7 +/- 1.5 hours, respectively. After oral administration, theC(max),t1/2 lambda z and bioavailability were 1.95 +/- 0.7 mu g/ml, 7.65 +/- 1.38 hours and 71.93 +/- 9.75%, respectively. In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) inC(max)(0.57 +/- 0.23 mu g/ml), AUC (5.73 +/- 2.26 mu g-h/ml) and bioavailability (31.92 +/- 14.19%). In the dogs studied, it is suggested that the dose 5 mg/kg of levofloxacin for both routes is inadequate to meet PK-PD targets for susceptible bacteria using breakpoints established by the Institute of Clinical and Laboratory Standards (CLSI).
dc.identifier.urihttp://repositoriodigital.uct.cl/handle/10925/3039
dc.language.isoen
dc.publisherTAYLOR & FRANCIS LTD
dc.sourceXENOBIOTICA
oaire.resourceTypeArticle
uct.catalogadorWOS
uct.indizacionSCI
Files
Collections
Migración Web of Science